Trending...
- 76 FENCE Expands in North Carolina with Strategic Franchise Growth Led by Regional Developer Drew Myers
- Celebrate Christmas 2024 with Exclusive Deals and Festive Offers
- Eva Garland Consulting Expands to New Office Space in Raleigh to Support Growing Accounting Team
JUPITER, Fla. - ncarol.com -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on ncarol.com
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on ncarol.com
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on ncarol.com
- Capital Realty Group Has An Outstanding October!
- The United States Environmental Protection Agency (USEPA) is SEBAC's 2024 Award for Excellence winner
- Author Riley G. Staliger Offers Tools to Escape Guilt-Driven Relationships AKA Obligationships Using Pop Culture
- Healthcare Consulting Firm, Coker, Announces Acquisition of NorthGauge Healthcare Advisors
- Kaplan Morrell Named Exclusive Workers' Compensation Firm for Greeley Fire Fighters
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on ncarol.com
- Drive for Gratitude Significantly Impacts Veterans Well-being
- The Voice of the Wooden Dragon is Latest Release from NFB Publishing
- AONE Fest 2024: Celebrating Creativity and Community at Red Dot Studios
- Alterra Retail Introduces Premium Baby Clothes Made from Organic Pima Cotton
- At Your Service Plumbing Honored with Silver Award in The Best of Pierce County
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on ncarol.com
- Ghostly Gamble: Nick Caden's Deadliest Halloween Mystery Yet
- Cornerstone Hospitality Solutions, Llc Receives Veteran Institute For Procurement Commercial Certification
- Summit Credit Union Reaffirms Commitment to Small Credit Unions and Women's Leadership with New $130,000 Contribution
- Upcoming Webinar: Family-Owned Businesses in Italy and Spain: Opportunities and Pitfalls for International Investors
- WYSIWYG Marketing Welcomes Ellen McColl as Director of Business Development
- Inc. Names BYLTup as a 2024 Power Partner Award Winner
- Gateway Center Arena Welcomes Atlantans To The City's Premier Sports and Entertainment Venue
- Support Literacy and Community Well-Being: Buy or Send a New Book to a Child in Need Today!
- WE In The World, Supported By Robert Wood Johnson Foundation, Calls Healthcare & Community Changemakers To Transform Structural Racism in Healthcare
- Arbutus Medical Launches Digit Revision SwiftKit™ to Streamline Trauma Care and Improve Emergency Department Throughput
- MarketTecNexus CEO's Digital Clone Introduces "AI Business Scale Up™," Services Redefining AI Transformation for Mid-Size Businesses
- Cresimore Joins Presidia Asset Management as Director of Business Development, and Investor Relations
- Los Defensores Champions Underserved Communities with the Launch of "Siempre Contigo" Initiative in Houston
- Natural Sweetener Health Trend on the Rise: Black Friday Special Discounts Are Here!
- First Citizens BancShares Declares Dividends
- TOKYO SKYTREE® is Now Selling Premium Traditional Performing Arts Experiences
- Vantiva and e& Deploy First eSIM-enabled 5G Fixed Wireless Access Gateway for United Arab Emirates Subscribers
- OpsVeda Announces General Availability Of Release 10.0 Of Its AI Powered Operations Command Center
- Celebrate Christmas 2024 with Exclusive Deals and Festive Offers
- Klatt Works, Executive Flightways, L2 Aviation, and Ametek Revolutionize Business Jet Safety with the First SAVED System STC for the G550